ClinicalTrials.gov
public full text
Public Domain
Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
The purpose of this study is to investigate the effect and the side effect profile of irinotecan and panitumumab administered every 3 weeks as 3rd line treatment for patients with metastatic colorectal cancer without KRAS mutations.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.#830248
- Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC#893783
- Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer#245518
- Combination Chemotherapy in Treating Patients With Colorectal Cancer#890844
- Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer#1009575
Record · ID 993142
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive